Cholesterol Medicine

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
 
Important Information About ZETIA

Site Map

Home

Efficacy Studies
EZ-PATH Results: LDL-C Efficacy
EZ-PATH Results: Efficacy in Other Lipid Parameters
EZ-PATH Results: Attainment of LDL-C <70 mg/dL
EZ-PATH Results: Hypothetical Patient Case
TEMPO Results: LDL-C Efficacy
TEMPO Results: Efficacy in Other Lipid Parameters
TEMPO Results: Attainment of LDL-C <100 mg/dL
TEMPO Results: Hypothetical Patient Case

Information About Titration
Selected Statin Titration Studies
Titration: 1-Year Retrospective Data

Learn About ZETIA
Multiple Studies
Mechanism of Action
LDL-C Efficacy of Monotherapy
Coadministration With Fenofibrate
LDL-C Efficacy: Patients Aged <65 and ≥65 Years
Efficacy in Other Lipids

Safety Profile, Tolerability, and Dosing
Selected Safety Information
Safety Profile and Tolerability: Patients Aged <65 and ≥65 Years
Dosage: Once-Daily Tablet

Clinical Studies
Journal Reprints

Managed Care Information
Formulary Status
Medicare Part D Formulary Status

Physician Resources
Merck OnCall ®
eMedical Forums
Request More Information
Order Samples

Patient Education Materials

Prescribing Information

Patient Information

Patient Site for ZETIA

Physician Site for VYTORIN® (ezetimibe / simvastatin)
This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.

For non-US health care professionals, click here.

ZETIA and VYTORIN are registered trademarks of MSP Singapore Company, LLC.

Merck/Schering-Plough Pharmaceuticals        Merck/Schering-Plough Pharmaceuticals        Merck/Schering-Plough Pharmaceuticals
MerckMedicus™, MerckSource®, and MerckServices® are trademarks of Merck & Co., Inc.

21050228(1)-06/10-ZET